BGP TRACP-5b BGP TRACP-5b P 0.05

Transcript

1 () Chin J Clinicians(Electronic Edition),October 15,2014,Vol.8,No OP OP BMD BGP-5b TRACP-5b OP 1 4 L1 4NFTH BMD BGP TRACP-5b P 0.05 OP L1 4 NF TH BMD BGP TRACP-5b P 0.05 L1 4 NF TH BMD BGP TRACP-5b P 0.05 BMD BGP TRACP-5b P 0.05 P 0.05 OP Effect value of calcitonin combined with alendronate on the osteoporosis Hu Yongyou. Department of Surgery, The People s Hospital of Yongchuan District, Chongqing , China zzzj73@sina.com AbstractObjective To observe the curative effect of calcitonin combined with alendronate on the osteoporosis (OP). Methods 120 patients with OP were selected from Jan 2011 to Jun They could be divided into three groups in order. The control group (n=40, the actual completion of 37 cases) was in calcitonin, the control group (n=40, the actual completion of 38 cases) was in alendronate, and the observation group (n=40, the actual completion of 38 cases) was in calcitonin combined with alendronate to compare the bone density (BMD), serum osteocalcin (BGP), tartrate resistant acid phosphatase-5b (TRACP-5b), pain symptoms, quality of life and untoward effect. Results Compared with the pretherapy, the lumbar vertebrae 1-4 (L1-4), neck of femur (NF), total hip (TH)'s BMD and scores of quality of life were significantly increased, and the BGP, TRACP-5b were significantly decreased after the treatment. There were significant differences between the groups (P<0.05). There were no significant differences in the L1-4, NF, TH s BMD, BGP, TRACP-5b and scores of quality of life between the groups in the pretherapy (P>0.05). Compared with the control group and control group, the L1-4, NF, TH s BMD and scores of quality of life (in addition to physiological functions) in the observation group were significantly higher, the BGP and TRACP-5b were significantly lower, and the pain symptoms were significantly better. There were significant differences between the groups (P<0.05). There were no significant differences between the control group and control group (P>0.05) in BMD, BGP, DOI: /cma.j.issn zzzj73@sina.com

2 3616 () Chin J Clinicians(Electronic Edition),October 15,2014,Vol.8,No.20 TRACP-5b, pain symptoms and scores of quality of life. There were no significant differences in the untoward effect between the three groups (P>0.05). Conclusion Calcitonin combined with alendronate for the OP, is safe, effective and worthy of popularization and application. Key wordsosteoporosis; Calcitonin; Bone density; Alendronate; Osteodynia osteoporosis OP [1] [2] % [3] OP OP OP 2011 [4] 1 4 L1 4 NF Ward BMD BMD 2.5 AKP BGP OP 1 6 OP OP 3 40 Novartis Pharma Schweiz AG. Switzerland H ml 50 IU50 IU/1 /d / 40 J mg/1 /1 / 30 min IU/1 /d / 1 /1 / 30 min D 3 D H mg/ 1 /1 /d H μg/1 /1 /d BMD X EXPERT-XL LUNAR L1 4 NF TH BMD2 BGP -5b TRACP-5b ELISA3 VAS 0 10 [5] SF SPSS 19.0 [% ] χ 2 x s t α 0.05 P

3 () Chin J Clinicians(Electronic Edition),October 15,2014,Vol.8,No OP P BMD 1 2 OP L1 4 NF TH BMD P 0.05 OP L1 4 NF TH BMD P 0.05 L1 4 NF TH BMD P 0.05 P OP BGP TRACP-5b P 0.05 OP BGP TRACP-5b P 0.05 BGP TRACP-5b P 0.05 P P 0.05 P % 52.6% 92.1% OP P 0.05 OP P 0.05 OP BMD g/m 2 x s L 1 4 NF TH t P t P t P ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± OP BMD L NF TH L NF TH OP BGP TRACP-5b x s BGP(ng/ml) TRACP-5b(U/L) t P t P ± ± ± ± ± ± ± ± ± ± ± ± OP BGP TRACP-5b BGP TRACP-5b BGP TRACP-5b

4 3618 () Chin J Clinicians(Electronic Edition),October 15,2014,Vol.8,No.20 OP Z= P=0.113Z= P=0.036Z= P=0.000 OP x s t P t P t P ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± OP SF P 0.05 P % % % χ P %3 7.9% 0 0 χ P [6] OP OP OP OP [1] OP OP [7] OP CT OP BMD BGP TRACP-5b OP [8]

5 () Chin J Clinicians(Electronic Edition),October 15,2014,Vol.8,No BMD [9] CT 32 BMD CT β- Ca 2+ β- [10] 67.6% 52.6% OP L1 4 NF TH BMD BGP TRACP-5b P 0.05 P 0.05 P 0.05 [5] BMD L1 4 NF TH [8] BGP TRACP-5b BGP TRACP-5b BMD OP [11] CT 2 3 [1],. [J]., 2013, 12(5): [2] Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis related fractures in the United States, [J]. J Bone Miner Res, 2007, 22(3): [3]. [J]., 2009, 3(3): [4]. (2011 )[J]., 2011, 4(1): [5],,. [J]., 2011, 2(3): [6] Silverman S, Christiansen C. Individualizing osteoporosis therapy[j]. Osteoporos Int, 2012, 23(3): [7] Betts AM, Clark TH, Yang J, et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis[j]. J Pharmacol Exp Ther, 2010, 333(1): [8],,. [J]., 2012, 33(15): [9] Karsdal MA, Henriksen K, Bay-Hensen AC, et al. Lessons learned from the development of oral calcitonin: The first tablet formulation of a protein in phase clinical trials[j]. J Clin Pharmacol, 2011, 51(4): [10],,,. [J]., 2009, 23(4): [11]. [J]., 2010, 18(8): J/CD